肿瘤标志物在肺癌诊断、疗效及预后评判中的意义

The Clinical Value of Tumor Makers in the Diagnosis ,Predic tion Response to Chemotherapy and Prognosis in Human Lung Cancer

目的 评价肿瘤标志物在肺癌诊断、疗效及预后中的临床价值。方法 采用放射免疫法检测 1 98例肺癌和 6 1例肺部非癌症疾病住院患者治疗前、后血清癌胚抗原 (CEA)、神经元特异性烯醇化酶 (NSE)、细胞角质蛋白 1 9片段 (Cy FRA2 1- 1)水平 ,然后进行分析和评价。结果 肺癌患者血清 CEA、NSE、Cy FRA2 1- 1水平明显高于肺部非癌症患者组 ,其中腺癌患者血清 CEA水平最高 ,小细胞肺癌患者血清 NSE水平最高 ,鳞癌患者血清 Cy FRA2 1- 1水平最高。结论 测定肺癌患者血清 CEA、NSE、Cy FRA2 1- 1水平对肺癌的诊断。

Objective To evaluate the clinical value of tumor markers on diagnosis,response to chemotherapy and prognosis in human lung cancer.MethodsThe serum levels of CEA,NSE and CyFRA\-\{21-1\} were assayed by radioimmunoassay before treatment and after treament in 198 lung cancer patients.ResultsThe CEA,NSE and CyFRA\-\{21-1\} levels were higher in lung cancer patients compared with benign patients group.The CEA level were the highest in adenocarcinoma patients.The NSE level were the highest in small cell lung cancer patients and CyFRA\-\{21-1\} level were the highest in squamous cell carcinoma patients.ConclusionThe CEA,NSE and CyFRA\-\{21-1\} assay were of important value in lung cancer patients on diagnosis,predict response to treatment and evaluate the porgnosis.